Pazopanib with            <scp>5‐FU</scp>            and oxaliplatin as first line therapy in advanced gastric cancer: A randomized            <scp>phase‐II</scp>            study—The            <scp>PaFLO</scp>            trial. A study of the Arbeitsgemeinschaft Internistische Onkologie            <scp>AIO‐STO</scp>            ‐0510

User: Guest

Title:: Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510
Document type:: Zeitschriftenaufsatz
Author(s):: Högner, Anica; Al‐Batran, Salah‐Eddin; Siveke, Jens T.; Lorenz, Mario; Bartels, Prisca; Breithaupt, Kirstin; Malfertheiner, Peter; Homann, Nils; Stein, Alexander; Gläser, Dietrich; Tamm, Ingo; Hinke, Axel; Vogel, Arndt; Thuss‐Patience, Peter
Journal title:: International Journal of Cancer
Year:: 2021
Journal volume:: 150
Journal issue:: 6
Pages contribution:: 1007-1017
Fulltext / DOI:: doi:10.1002/ijc.33864
Publisher:: Wiley
E-ISSN:: 0020-7136; 1097-0215
Date of publication:: 15.11.2021
BibTeX

Occurrences:

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510